盐酸吉西他滨联合顺铂对非小细胞肺癌外周血调节性T细胞水平影响的研究

目的探讨盐酸吉西他滨联合顺铂对非小细胞肺癌外周血调节性T细胞水平的影响，从而为相关临床研究提供依据和参考。方法本次研究人选的病例均为本院2009年1月～2012年12月收治的非小细胞肺癌患者50例（非小细胞癌组），同期健康体检者34例（健康对照组），观察记录全部研究对象以及患者实施治疗前后CD4^＋CD25^＋Foxp3^＋／CD4^＋水平，并对相关数据进行统计学分析。结果健康对照组的CD4^＋CD25^＋Foxp3^＋／CD4^＋显著低于非小细胞癌组，且组间比较差异有统计学意义；不同类型的非小细胞癌患者实施治疗后，较治疗前该项指标水平得到显著降低，且治疗前后比较差异均有统计学意义（P〈0．05）。结论盐酸吉西他滨联合顺铂的治疗方案可以显著调节非小细胞肺癌患者的外周血调节性T细胞水平，可有效调节患者的肿瘤免疫耐受，从而显著改善患者的免疫功能，是临床治疗非小细胞肺癌的理想选择。

Impact study of gemcitabine hydrochloride combining with cis-platinum on levels of regulatory T cells in peripheral blood in patients with nonsmall cell lung cancer

Objective To further explore the impact of gemcitabine hydrochloride combining with cis-platinum on levels of regulatory T ceils in peripheral blood in patients with non-small cell lung cancer （NSCLC） aiming at providing basis and reference for related clinical researches. Methods 50 NSCLC patients admitted into our hospital from January 2009 to December 2012 were selected.Another 34 healthy participants in the same period were chosen as healthy control group.Clinical data from all participants and levels of CD4^＋CD25^＋Foxp3^＋/CD4^＋ before and after therapy were observed and recorded, and the related data were comparatively analyzed. Results With regard to CD4^＋CD25^＋Foxp3^＋/CD4^＋, the level in the healthy control group was lower than that in the NSCLC group with a statistical difference.After treatment,levels of CD4^＋CD25^＋Foxp3^＋/CD4^＋ in different types of NSCLC patients remarkably decreased in comparison with those before treatment respectively,which all displayed statistical differences （P〈0.05）. Conclusion Therapeutic regimen of gemcitabine hydrochloride combining With cis-platinum can remarkably regulate regulatory T cells in peripheral blood in NSCLC patients and tumor immune tolerance,and finally improve patient＇s immunity,which is an optimal option for NSCLC patients in clinic.